Medifoxamine

CHEMBL85231 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
257.3 g/mol
LogP
3.8
Phase
4

This antidepressant was investigated in France for its ability to inhibit the reuptake of dopamine and serotonin, potentially offering a novel mechanism for treating depression. It did not receive widespread approval.

Molecular Weight

257.3300 g/mol

LogP

3.80

TPSA

21.70 Ų

Lipinski RO5

Pass

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CC(Oc1ccccc1)Oc1ccccc1

InChI

InChI=1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3

Molecular Formula

C16H19NO2

HBD / HBA

- / 3

Rotatable Bonds

6

Heavy Atoms

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This antidepressant was investigated in France for its ability to inhibit the reuptake of dopamine and serotonin, potentially offering a novel mechanism for treating depression. It did not receive widespread approval.

Yes, Medifoxamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL85231. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 36109. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.